TP53 and neoplasm: Mutations in PIK3CA (19.6%), MYC (15.5%), TP53 (15.5%), and PTEN (14.4%) are also seen, as are tumors with intermediate or high tumor mutational burden (18.6%), at times also showing DNA MMR deficiency (Eskander et al. 2020).